First patient recruited in global AMD trial
The new treatment involves stimulating cells in the retina with light in a process called ‘photobiomodulation.’
Read More
Tag: AMD
First patient dosed in Gyroscope Therapeutics’ AMD study
Gyroscope Therapeutics has announced that the first patient has been dosed in its Phase I/II FOCUS study for dry age-related macular degeneration (AMD).
Read More
Allergan, Molecular Partners’ AMD drug non-inferior to Lucentis
Allergan, Molecular Partners’ abicipar has shown non-inferiority to Novartis’ Lucentis but with fewer injections in late-stage trials involving patients with neovascular age-related macular degeneration.
Read More
Charities link with BenevolentAI to discover new AMD therapies
BenevolentAI has teamed up with Action Against AMD* to find treatments and a potential cure for age-related macular degeneration, the leading cause of blindness in the UK.
Read More
Novartis, NHS joint working pact delivers new eye service
People living in Ayrshire and Arran who have some of the most common forms of avoidable sight loss will now be able to benefit from a new facility designed specifically for the eye service through a partnership between Novartis Pharmaceuticals UK and the NHS.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
